RxDoctor Payments Data

Satinder Bhatia, MD

Cardiovascular Disease · Beverly Hills, CANPI 1538131693

Payments from drug & device makers

$2,358in general payments, 2019–2025

Across 108 payments — averaging $21.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$384
  • Amgen$368
  • E.r. Squibb & Sons, L.L.C.$245
  • Novartis$198
  • Alnylam Pharmaceuticals Inc.$142
  • Edwards Lifesciences$104
  • plus $917 from 21 others

What the payments were for

  • Food & beverage$2,358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,358 in reported general payments places this provider in the 45th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,686,634
Medicare patients
991
Services billed
35,746

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$67,391
MounjaroTirzepatide50$66,007
Repatha SureclickEvolocumab66$63,842
OzempicSemaglutide46$61,484
EntrestoSacubitril/Valsartan36$44,348
WegovySemaglutide21$37,381
FarxigaDapagliflozin Propanediol27$21,299
LinzessLinaclotide15$16,495
Praluent PenAlirocumab18$15,546
Rosuvastatin Calcium286$4,828
Ezetimibe129$4,576
Telmisartan66$1,810
SynthroidLevothyroxine Sodium22$1,667
Midodrine Hcl27$1,524
Nebivolol Hcl11$1,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$25$98,86567 claims
PfizerEliquis$384$67,39157 claims
Lilly USA, LLCMounjaro$68$66,00750 claims
NovartisEntresto$198$44,34836 claims
AstraZenecaFarxiga$51$21,29927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →